Literature DB >> 16181613

Honokiol inhibits TNF-alpha-stimulated NF-kappaB activation and NF-kappaB-regulated gene expression through suppression of IKK activation.

Anfernee Kai-Wing Tse1, Chi-Keung Wan, Xiao-Ling Shen, Mengsu Yang, Wang-Fun Fong.   

Abstract

Honokiol, a small molecular weight lignan originally isolated from Magnolia officinalis, shows anti-angiogenic, anti-invasive and anti-proliferative activities in a variety of cancers. In this study, we investigated whether honokiol affects the transcription factor nuclear factor-kappa B (NF-kappaB) which controls a large number of genes involved in angiogenesis, metastasis and cell survival. We observed that the tumor necrosis factor-alpha (TNF-alpha)-induced NF-kappaB activation was blocked by honokiol in four different cancer cell lines as evidenced by EMSA. Honokiol did not directly affect the NF-kappaB-DNA binding. Immunoblot experiments demonstrated that honokiol inhibited the TNF-alpha-stimulated phosphorylation and degradation of the cytosolic NF-kappaB inhibitor IkappaBalpha. Furthermore, honokiol suppressed the intrinsic and TNF-alpha-stimulated upstream IkappaB kinases (IKKs) activities measured by a non-radioactive kinase assay using immunoprecipitated IKKs, suggesting a critical role of honokiol in abrogating the phosphorylation and degradation of IkappaBalpha. In a HeLa cell NF-kappaB-dependent luciferase reporter system, honokiol suppressed luciferase expression stimulated by TNF-alpha and by the transient transfection and expression of NIK (NF-kappaB-inducing kinase), wild type IKKbeta, constitutively active IKKalpha and IKKbeta, or the p65 subunit. Honokiol was also found to inhibit the nuclear translocation and phosphorylation of p65 subunit of NF-kappaB. RT-PCR results showed that honokiol suppressed NF-kappaB-regulated inflammatory and carcinogenic gene products including MMP-9, TNF-alpha, IL-8, ICAM-1 and MCP-1. In line with the observation that NF-kappaB activation may up-regulate anti-apoptotic genes, it was shown that honokiol enhanced TNF-alpha-induced apoptotic cell death. In summary, our results demonstrate that honokiol suppresses NF-kappaB activation and NF-kappaB-regulated gene expression through the inhibition of IKKs, which provides a possible mechanism for its anti-tumor actions.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16181613     DOI: 10.1016/j.bcp.2005.08.011

Source DB:  PubMed          Journal:  Biochem Pharmacol        ISSN: 0006-2952            Impact factor:   5.858


  38 in total

1.  Honokiol Radiosensitizes Squamous Cell Carcinoma of the Head and Neck by Downregulation of Survivin.

Authors:  Xu Wang; Jonathan J Beitler; Wen Huang; Guo Chen; Guoqing Qian; Kelly Magliocca; Mihir R Patel; Amy Y Chen; Jun Zhang; Sreenivas Nannapaneni; Sungjin Kim; Zhengjia Chen; Xingming Deng; Nabil F Saba; Zhuo Georgia Chen; Jack L Arbiser; Dong M Shin
Journal:  Clin Cancer Res       Date:  2017-11-27       Impact factor: 12.531

2.  Honokiol inhibits epithelial-mesenchymal transition in breast cancer cells by targeting signal transducer and activator of transcription 3/Zeb1/E-cadherin axis.

Authors:  Dimiter B Avtanski; Arumugam Nagalingam; Michael Y Bonner; Jack L Arbiser; Neeraj K Saxena; Dipali Sharma
Journal:  Mol Oncol       Date:  2014-01-15       Impact factor: 6.603

3.  Honokiol inhibits epidermal growth factor receptor signaling and enhances the antitumor effects of epidermal growth factor receptor inhibitors.

Authors:  Rebecca J Leeman-Neill; Quan Cai; Sonali C Joyce; Sufi M Thomas; Neil E Bhola; Daniel B Neill; Jack L Arbiser; Jennifer R Grandis
Journal:  Clin Cancer Res       Date:  2010-04-13       Impact factor: 12.531

4.  Honokiol Decreases Lung Cancer Metastasis through Inhibition of the STAT3 Signaling Pathway.

Authors:  Jing Pan; Yongik Lee; Qi Zhang; Donghai Xiong; Tina C Wan; Yian Wang; Ming You
Journal:  Cancer Prev Res (Phila)       Date:  2016-11-14

5.  Therapeutic Action of Honokiol on Postoperative Ileus via Downregulation of iNOS Gene Expression.

Authors:  Taiki Mihara; Shoma Mikawa; Noriyuki Kaji; Mari Endo; Tetsuro Oikawa; Jan Tong-Rong; Hiroshi Ozaki; Masatoshi Hori
Journal:  Inflammation       Date:  2017-08       Impact factor: 4.092

6.  Indomethacin sensitizes TRAIL-resistant melanoma cells to TRAIL-induced apoptosis through ROS-mediated upregulation of death receptor 5 and downregulation of survivin.

Authors:  Anfernee Kai-Wing Tse; Hui-Hui Cao; Chi-Yan Cheng; Hiu-Yee Kwan; Hua Yu; Wang-Fun Fong; Zhi-Ling Yu
Journal:  J Invest Dermatol       Date:  2013-11-08       Impact factor: 8.551

7.  Different redox states in malignant and nonmalignant esophageal epithelial cells and differential cytotoxic responses to bile acid and honokiol.

Authors:  Gang Chen; Julie Izzo; Yusuke Demizu; Feng Wang; Sushovan Guha; Xifeng Wu; Mein-Chie Hung; Jaffer A Ajani; Peng Huang
Journal:  Antioxid Redox Signal       Date:  2009-05       Impact factor: 8.401

8.  KIOM-79 Prevents Lens Epithelial Cell Apoptosis and Lens Opacification in Zucker Diabetic Fatty Rats.

Authors:  Junghyun Kim; Chan-Sik Kim; Eunjin Sohn; Hyojun Kim; Il-Ha Jeong; Jin Sook Kim
Journal:  Evid Based Complement Alternat Med       Date:  2010-09-07       Impact factor: 2.629

9.  Honokiol suppresses survival signals mediated by Ras-dependent phospholipase D activity in human cancer cells.

Authors:  Avalon Garcia; Yang Zheng; Chen Zhao; Alfredo Toschi; Judy Fan; Natalie Shraibman; H Alex Brown; Dafna Bar-Sagi; David A Foster; Jack L Arbiser
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

Review 10.  Honokiol, a multifunctional antiangiogenic and antitumor agent.

Authors:  Levi E Fried; Jack L Arbiser
Journal:  Antioxid Redox Signal       Date:  2009-05       Impact factor: 8.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.